MAGI1

MAGI1 is a multi-domain scaffolding protein characterized by an N-terminal guanylate kinase (GuK) domain, two WW domains, and six PDZ domains that mediate protein-protein interactions. These domains allow MAGI1 to bind a diverse array of partners, including cell adhesion molecules, receptors, and signaling enzymes, thereby organizing signaling complexes at specialized membrane sites such as tight junctions and synapses.¹

In epithelial cells, MAGI1 localizes to tight junctions and interacts with junctional proteins like claudins and ZO-1, contributing to barrier integrity. In neurons, it is enriched at postsynaptic densities, where it regulates receptor clustering and synaptic plasticity. MAGI1 also interacts with PTEN and β-catenin, linking it to pathways controlling cell proliferation and apoptosis.²

MAGI1 is frequently downregulated or lost in several human cancers, including hepatocellular carcinoma, colorectal cancer, and breast cancer, suggesting a tumor suppressor role. Its loss promotes cell migration, invasion, and epithelial-mesenchymal transition (EMT), partly through deregulation of PTEN/AKT signaling and increased β-catenin transcriptional activity.³

In addition to cancer, MAGI1 has been implicated in kidney disease and viral infection. It interacts with the hepatitis C virus NS3 protein and may influence viral replication. MAGI1 also regulates podocyte function in the kidney, and its disruption contributes to proteinuria and glomerular disease.⁴

MAGI1 expression is regulated at multiple levels, including transcriptional control by p53 and microRNAs such as miR-200 family members. Alternative splicing generates several isoforms with distinct domain compositions and tissue-specific expression patterns, adding functional diversity. For instance, MAGI1 isoforms lacking certain PDZ domains exhibit altered binding affinities for partners like β-catenin.⁵

Post-translational modifications, including phosphorylation and ubiquitination, modulate MAGI1 stability and interactions. Proteasomal degradation of MAGI1 is enhanced in some cancers, contributing to its reduced levels. Understanding these regulatory mechanisms is crucial for developing targeted therapies that restore MAGI1 function.⁶

Beyond its canonical roles, MAGI1 participates in less-studied processes such as angiogenesis and immune synapse formation. It interacts with vascular endothelial growth factor receptor 2 (VEGFR2) and modulates endothelial cell migration, influencing tumor angiogenesis. In T cells, MAGI1 is recruited to the immunological synapse and may regulate T cell activation.⁷

MAGI1 also has a role in the nervous system beyond synaptic function: it is involved in dendritic spine morphogenesis and has been linked to autism spectrum disorder and schizophrenia through genetic association studies. Additionally, MAGI1 is a target of the Epstein-Barr virus latent membrane protein 2A, which may contribute to viral oncogenesis.⁸

PDZ domain

A common structural domain that mediates protein-protein interactions, often binding to C-terminal motifs of target proteins.

Scaffolding protein

A protein that organizes multiple signaling molecules into complexes, facilitating efficient signal transduction.

Tight junction

A cell-cell junction that seals adjacent epithelial cells, controlling paracellular transport.